<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864121</url>
  </required_header>
  <id_info>
    <org_study_id>PI15088</org_study_id>
    <nct_id>NCT02864121</nct_id>
  </id_info>
  <brief_title>Oncogenous HPV DNA Integration (Intégration De l'ADN Des HPV Oncogènes)</brief_title>
  <acronym>IDAHO</acronym>
  <official_title>Association Between High-risk HPV Genome Integration Detected by Molecular Combing and Cervical Lesions Severity and/or Evolution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-risk human papillomavirus (HR-HPV) are involved in cervical cancer development.
      Integration of HR-HPV DNA in cellular genomes is considered as a major event in the cervical
      cancer development. The aim of this study is to validate the integration of the HPV-HR as an
      appropriate biomarker of the severity of precancerous lesions and progression of cervical
      lesions towards cervical cancer. HR-HPV integration status will be analyzed by Molecular
      Combing technology, which allows direct and high-resolution visualization of the integration
      of high-risk HPV genomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">December 17, 2019</completion_date>
  <primary_completion_date type="Actual">December 17, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>presence of high-risk papillomavirus in the analysis of cervical smear</measure>
    <time_frame>during 36 months after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>integration of genome of high-risk papillomavirus detected in cervical smear according molecular combing</measure>
    <time_frame>during 36 months after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>presence and severity of cervical lesion according to results of cervical smear, colonoscopy and histological analysis</measure>
    <time_frame>during 36 months after inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">407</enrollment>
  <condition>Abnormal Cytology</condition>
  <arm_group>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all patients included in IDAHO study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>all patients included in IDAHO study</intervention_name>
    <arm_group_label>arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women aged from 25 to 65 years

          -  consulting in a gynecological-obstetrical service of one of the investigator center
             for a colposcopy reflex after an abnormal cytology dating of less than 6 months and
             more than 1 month

          -  signature of the informed consent

          -  affiliated to Social Security

        Exclusion Criteria:

          -  women vaccinated against HPV

          -  women who received a treatment for a cervical pathology followed by a normal

          -  women with a known positive HIV test

          -  women suffering from a chronic pathology that generate immunosuppression

          -  Women currently treated with immunosuppressors

          -  Women treated with corticoids currently or dating of less than 6 months

          -  protected by law

          -  pregnant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High-risk human papillomavirus</keyword>
  <keyword>Integration of HR-HPV DNA</keyword>
  <keyword>biomarker of severity</keyword>
  <keyword>biomarker of evolution</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

